Why Amplia Therapeutics (ASX:ATX) Has Received a A$4.78 Million R&D Tax Incentive Rebate for Its Pancreatic Cancer Programme

Sonal Goyal

23 October 2026 05:42 PM AEDT

Why Amplia Therapeutics (ASX:ATX) Has Received a A$4.78 Million R&D Tax Incentive Rebate for Its Pancreatic Cancer Programme

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Amplia Therapeutics received A$4,778,235.52 from the Australian Taxation Office under the R&D Tax Incentive for the year ended 31 March 2026.
The company said the funds will support the ACCENT and AMPLICITY clinical trials, the ACCENT-MINI trial, the PRROSE study and combination studies with Lilly.
The announcement does not state the company's total cash balance after receipt.

Amplia Therapeutics Limited (ASX:ATX) has received A$4,778,235.52 from the Australian Taxation Office under the Research and Development Tax Incentive, covering the financial year ended 31 March 2026. The company announced the receipt on 22 October 2026.

The incentive provides a refundable tax offset of 43.5 per cent to 48.5 per cent on eligible research and development expenditure. Amplia says the eligible spending related to its focal adhesion kinase (FAK) inhibitors, narmafotinib (AMP945) and AMP886, with most of the activity tied to ongoing Clinical Trials of narmafotinib in advanced pancreatic cancer. The payment is a refund of past expenditure rather than new Equity or grant funding, and the announcement does not state the company's total cash balance after receipt.

How the funds will be used

The company says the money will support its clinical programme, and that it will contribute to the further progression of both the ACCENT and AMPLICITY clinical trials. It also lists the ACCENT-MINI trial, the PRROSE study, combination studies with Lilly and other supporting research and development activities as areas of use.

The clinical programmes

The ACCENT trial tests narmafotinib with gemcitabine and Abraxane as a first-line treatment for advanced pancreatic cancer. Amplia reports a 36 per cent response rate and median overall survival of 11.1 months. These are company-reported results from an ongoing trial. The AMPLICITY trial combines narmafotinib with the FOLFIRINOX regimen as a first-line treatment for advanced pancreatic cancer and is being run at sites in Australia.

Drug and company background

Amplia Therapeutics (ASX:ATX) describes narmafotinib as its FAK inhibitor, saying it is highly potent and selective. FAK is overexpressed in pancreatic cancer and is being studied across several solid tumours. Amplia develops FAK inhibitors for cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer, and notes the role of FAK in chronic diseases such as idiopathic pulmonary fibrosis.

What the announcement does not say

The announcement is a funding update. It does not report new trial data, give updated enrolment numbers, or set out dates for upcoming trial readouts. Narmafotinib has not been approved for use, and all clinical progress described is at the trial stage. Details of the company's overall cash position, trial timelines or expected data releases are not included.

The ACCENT-MINI trial and the PRROSE study are listed separately, as are the Lilly combination studies, which the announcement mentions without describing their design, size or timing. How much of the rebate is allocated to each trial or study is not stated.

The offset is calculated on eligible spending in the year ended 31 March 2026. The announcement does not state whether the refund changes the company's cash runway, and it does not discuss any further Capital raising. The company described all trial results as company-reported.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.